Perrigo CEO Murray Kessler Photo: Perrigo PR Perrigo launches generic version of Teva's ProAir

ProAir HFA is one of Teva's important branded products.

Dror Ben-Asher RedHill buys AstraZeneca constipation drug rights

The Israeli drug developer will pay $67.5 million for Movantik, which treats opioid-induced constipation.

Shai Novik Photo: Eyal Yitzhar Enlivex plummets after raising cash at discount

Enlivex Therapeutics exploited yesterday's rise in its share price to raise $8 million.

Yaron Pereg / Photo: PR Cancer treatment co Kahr Medical raises $18m

The round was led by Flerie Invest AB, Oriella Limited, Hadasit Bio-Holdings, Pavilion Capital, and Mirae Asset Venture Investment.

Teva Teva digital asthma inhaler wins FDA nod

The ArmonAir Digihaler is for the treatment of asthma in patients 12 years and older.

Biotech development, photo: Shutterstock Drug developer PolyPid to file for Wall Street IPO

The company raised $50 million six months ago from its existing shareholders, and has now raised a total of $105 million.

Shai Novik Photo: Eyal Yitzhar Israel's Enlivex reports drug could help COVID-19 patients

Enlivex Therapeutics is increasing production of Allocetra, for treating patients with multisystem failure.

Coronavirus in Japan  / Photo: Reuters Gov't has spent NIS 100m to keep virus out of Israel

The Israeli economy will be hit hard by the growing effects of the coronavirus, even if the illness is successfully kept out of the country, economists warn.

Teva Photo: Sivan Faraj Teva shed 37% of Israel workforce in two years

Teva had 3,961 employees in Israel at the end of 2019, a reduction of 2,284  in two years, including 932 in 2019.

The streets of Beijing / Photo: Reuters Israel refuses entry to Korean Air passengers

The rapid spread of coronavirus COVID-19 in South Korea led the Israeli authorities to send a Korean Air plane and its 200 Korean passengers back to Seoul yesterday evening.

Anat Cohen-Dayag Compugen expands agreement with BMS

Israeli drug discovery company Compugen is conducting three cancer treatment trials this year, two of them with Bristol-Myers Squibb.

Medical devices Photo: Shutterstock ASAP Creative Integer buys Israeli medical device co Inomec

Inomec will become Integer's Israel development and sales center.

Kare Schultz Photo: Shlomi Yosef Teva CEO: We have to launch new products

Kare Schultz told Teva's annual press conference that streamlining and optimization won't be enough to get the company back to substantial growth.

Mori Arkin and Uri Geiger Exalenz Bioscience sold at NIS 165m valuation

The price at which the company is being sold is 97% lower than the price at which trading in the share began in 2007.

dental care Teeth whitening co Mavrik Dental Systems raises $30m

Global life science investment group Ally Bridge Group has invested $70 million in two Israeli companies.

drug development Israeli co NeoTX Therapeutics raises $45m

The Rehovot-based company is leveraging its proprietary Selective T cell Redirection (STR) platform to develop targeted anticancer immunotherapies.

Noam Zilbershtain / Photo: PR GE expands advanced imaging activities in Israel

The Israel Innovation Authority has granted GE NIS 50 million to expand its Rehovot center.

Copaxone Proneuron to sue Teva for billions in Copaxone damages

A court ordered Teva to restore the Copaxone rights for treatment of diseases other than multiple sclerosis to Proneuron, but the patent has expired, rendering the rights useless.

Warren Buffett Photo: ASAP Creative Value of Warren Buffett's position in Teva jumps

However, Berkshire Hathaway still has a loss on paper on its investment in Teva of about $230 million.

Tomer Hertz Is it worth getting vaccinated against flu?

Ben Gurion University researcher Dr. Tomer Hertz says flu jabs, like vaccinations against childhood diseases, are a social act that helps prevent infecting others.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018